1065474-61-4

Upstream product

• 35943-35-2 triciribine 
• 1065474-32-9 5'-O-(tert-butyldimethylsilyl)-[6-amino-4-methyl-8-(β-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine] 
• 770-12-7 O-phenyl phosphorodichloridate 
• 123-76-2 levulinic acid 
• 6306-52-1 L-valine methylester hydrochloride 
• 40608-06-8 levulinic anhydride 
• 1065474-35-2 4-methyl-6-amino-8-[5'-O-(tert-butyldimethylsilyl)-2',3'-O-dilevylinyl-β-D-ribofuranosyl]pyrrolo[4,3,2-d]pyrimidino[4,5-c]pyridazine 
• 1065474-37-4 4-methyl-6-amino-8-[2',3-O'-dilevylinyl-β-D-ribofuranosyl]pyrrolo[4,3,2-d]pyrimidino[4,5-c]pyridazine 
• 261910-17-2 chlorophenylphosphoryl (P->N)-L-valine methyl ester 

Downstream Products

• 1065474-31-8 4-methyl-6-amino-8-[5'-O-(phenylphosphoryl (P->N)-L-methyl ester valine)-β-D-ribofuranosyl]pyrrolo[4,3,2-d]pyrimidino[4,5-c]pyridazine 

Relevant academic research and scientific papers

Expedient total synthesis of triciribine and its prodrugs

Triciribine (TCN, 1) and its monophosphate (TCNP, 2) are ricyclic nucleotide derivatives that have potential antineoplastic activity. Triciribine inhibits the phosphorylation, activation, and signaling of Akt-1, -2, and -3, which may result in the inhibition of Akt-expressing tumor cell proliferation. Both TCN and TCNP have very low bioavailability, and the development of both drugs as intravenous (IV) treatments was halted because of the toxicity induced by the high doses needed for their use as general cytotoxic agents. This publication describes an expedient and straightforward total synthesis of amino acid prodrugs (3, 4) of TCN and TCNP. In our study, both the prodrugs significant improved the plasma exposure of the parent drugs and the prodrugs.Copyright TSRL Inc.

PRODRUGS OF TRICIRIBINE AND TRICIRIBINE PHOSPHATE

A prodrug composition is provided which includes a pharmaceutical species and an amino acid having a covalent bond to the pharmaceutical species. Particular pharmaceutical species are 6- amino-4-methyl-8-(beta.-D-ribofuranosyl)pyrrolo[4,3,2-de]pyrimido[4,5-c]pyridazine, also known as TCN and by the trade name tricirinine; as well as the 5 'phosphate of tricirine. TCN and TCNP prodrugs of the present invention have increased bioavailability compared to the parent TCN and TCNP. The inventive prodrug is transported from the gastrointestinal lumen by a specific transporter and is enzymatically cleaved to yield TCN or TCNP, such that TCN or TCNP is delivered to the individual.